Ciprofloxacin Kabi må kun anvendes til patienter med epilepsi eller andre patologiske forandringer af centralnervesystemet (f. eks. nedsat krampetærskel, forhistorie af epileptiske anfald, nedsat cerebral blodgennemløb, ændringer i hjernestruktur eller stroke) efter omhyggelig fordele/ ulempe afvejning, da muligheden for bivirkninger i centralnervesystemet indebærer en øget risiko for disse patienter.
In patients with epilepsy or other lesions of the central nervous system (e. g. reduced convulsion threshold, a history of epileptic seizures, diminished cerebral bloodflow, changes in brain structure or stroke), ciprofloxacin is only to be used after carefully weighing the benefits against the risk, because the possibility of central nervous side effects puts these patients at increased risk.